WNT5A and prostate cancer: Foxy-5, a Wnt5a mimicking hexapeptide, impairs the migration and invasion of breast cancer without affecting apoptosis or proliferation by reconstituting Wnt5a signaling [221] and has entered phase I clinical trials (NCT02020291 and NCT02655952) for metastatic breast, colorectal and prostate cancer treatment and a phase II clinical trial (NCT03883802) for Wnt5a-low colon cancer neoadjuvant therapy.